Johnson & Johnson vs TJ Maxx
Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
TJX Companies (NYSE: TJX) flagship off-price banner; parent reported $56.4B revenue FY2025 (+4%); 5,085 stores globally; treasure hunt retail model with constantly rotating merchandise mix and 131 new locations added in FY2025.
About
TJ Maxx is the flagship retail banner of TJX Companies, America's largest off-price retailer, founded in 1976 and headquartered in Framingham, Massachusetts. The brand was built on the "treasure hunt" retail model: buying excess inventory, overruns, and closeouts from manufacturers and department stores at steep discounts, then passing those savings to shoppers in a constantly rotating merchandise mix. This opportunistic buying strategy — executed by one of retail's largest buying organizations — is the core competitive technology that competitors cannot easily replicate.\n\nTJ Maxx stores carry apparel, accessories, footwear, home goods, beauty, and giftware across thousands of locations in the US, with TJX's broader portfolio also including Marshalls, HomeGoods, HomeSense, and Sierra. The physical store experience — browsing through unpredictable inventory to find brand-name items at 20–60% below department store prices — creates the addictive treasure hunt dynamic that drives frequent repeat visits. This model has proven highly durable against e-commerce disruption, as the discovery experience does not translate well to online retail.\n\nTJX Companies generated $56.4B in revenue in FY2025, a 4% increase, operating over 5,085 stores globally with 131 net new locations added. The company's off-price model has thrived as value-conscious consumers trade down from department stores and as retail inventory gluts create buying opportunities. TJ Maxx remains the dominant brand within TJX's portfolio and a bellwether of the off-price retail sector's resilience across economic cycles.
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.